Renaissance Capital logo

Marinus Pharmaceuticals Priced, Nasdaq: MRNS

Early-stage biotech developing an add-on therapy for epilepsy.

Industry: Health Care

First Day Return: 0.0%

Early-stage biotech developing an add-on therapy for epilepsy.

Marinus Pharmaceuticals (MRNS) Performance

Created with Highcharts 10.3.2Chart context menuMRNS vs. IPO Index (IPOUSA)20152016201720182019202020212022202320242025-100%0%+ 100%+ 200%+ 300%View 5 days5dView 1 month1mView 3 months3mView year to dateYTDView 1 year1yView allAllRenaissance IPO IndexOur ETF tracks the IPO Index